Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 3 of 1,261
  1. WO 2026082899

    ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE

    BIONTECH SE [DE] · Granted Apr 23, 2026 · Expires Apr 18, 2046

    granted
  2. US 20260108463

    NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Apr 23, 2026 · Expires Apr 18, 2046

    granted
  3. WO 2026085433

    PROCÉDÉS POUR PRÉPARER DES CONJUGUÉS OLIGONUCLÉOTIDIQUES

    BIOGEN MA INC [US] · Granted Apr 23, 2026 · Expires Apr 18, 2046

    granted
  4. WO 2026082715

    DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Apr 23, 2026 · Expires Apr 18, 2046

    granted
  5. WO 2026078165

    CONJUGUÉS COMPRENANT DES LIANTS CLIVABLES

    ASTRAZENECA AB [SE] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  6. WO 2026078615

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  7. WO 2026078163

    CONJUGUÉS COMPRENANT DES LIANTS

    ASTRAZENECA AB [SE] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  8. WO 2026078619

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  9. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  10. WO 2026080794

    COMPOSÉS CHIMIQUES UTILES POUR DÉGRADER DES PROTÉINES

    BRISTOL MYERS SQUIBB CO [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  11. WO 2026078159

    AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT

    ABLYNX NV [BE] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  12. WO 2026075950

    SCHÉMA POSOLOGIQUE POUR AGENT ANTI-DLL3

    AMGEN INC [US] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  13. WO 2026075941

    DÉRIVÉS DE PYRIDAZINONE EN TANT QU'INHIBITEURS DE PAD4

    BRISTOL MYERS SQUIBB CO [US] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  14. US 20260097057

    COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS

    ASTRAZENECA AB [SE] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  15. US 20260096994

    SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES

    BOEHRINGER INGELHEIM INT [DE] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  16. AU 2024342196

    NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

    ABBVIE GROUP HOLDINGS LTD [BM] · Granted Apr 2, 2026 · Expires Mar 28, 2046

    granted
  17. WO 2026068864

    DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE

    BIONTECH SE [DE] · Granted Apr 2, 2026 · Expires Mar 28, 2046

    granted
  18. WO 2026072909

    PROTÉINES DE LIAISON À FLT1 ET MÉTHODES D'UTILISATION

    AMGEN INC [US] · Granted Apr 2, 2026 · Expires Mar 28, 2046

    granted
  19. WO 2026068294

    PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ

    BAYER AG [DE] · Granted Apr 2, 2026 · Expires Mar 28, 2046

    granted
  20. WO 2026062193

    COMPOSITIONS ET PROCÉDÉS

    BIONTECH SE [DE] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  21. WO 2026062071

    ANTAGONISTES DE TNFR1 ET AGONISTES DE TNFR2 POUR LE TRAITEMENT DE LA DOULEUR AIGUË

    RESANO GMBH [DE] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  22. US 20260083736

    GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY

    BOEHRINGER INGELHEIM INT [DE] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  23. WO 2026062034

    NANOPARTICULES DE PROTÉINE AFFICHANT DES ANTIGÈNES DE MALADIE DE LYME

    BAVARIAN NORDIC AS [DK] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  24. WO 2026057588

    POLYTHÉRAPIE À BASE DE CLASCOTÉRONE ET DE MINOXIDIL POUR LE TRAITEMENT DE LA PERTE DES CHEVEUX

    CASSIOPEA S P A [IT] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.